ReviewClinical pharmacology and therapeutics2025
A Fast Path from Innovation to Safe and Effective Medicines.
Review in Clinical pharmacology and therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Regulatory Research Priorities for AI Use in the Medicine Lifecycle: A European Perspective with Global Relevance.Clinical pharmacology and therapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Consistent progress in medicines development has allowed both for de novo treatment options and for the refinement of existing products that improve effectiveness or reduce harm. Nonetheless, unmet medical needs persist, particularly in rare diseases, pediatrics and underserved populations. The many promises of pharmacological, technological, and regulatory innovation spark new hope for patients and doctors searching for treatments, and it is therefore essential that progress made translates into the availability of new and improved medicines. We here present our vision for accelerating the path from innovation to safe and effective medicines. Our vision is driven by the continued and transparent collaboration between regulators, academia, industry, patients, and healthcare professionals. Through concrete examples and strategic initiatives, we illustrate how the EMA works with stakeholders to support continuous evolution of regulatory science, contribute to patient-focused refinements in evidence generation and medicines assessments, and engage in forward-looking initiatives that monitor and examine innovative developments. The ultimate goal is to future-proof the regulatory ecosystem and ensure that scientific progress translates into meaningful health outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.